Diversified clinical-stage immunology company INmune Bio (NASDAQ: INMB) is on a mission to develop
novel immunotherapies that reprogram patients’ innate immune systems to enable
them to fight cancer and Alzheimer’s disease. A recent article further
discussing the company reads, “Innate is an immediate, nonspecific, initial
response that serves as a first line of defense against infection and cancer.
Most drug-development programs concentrate on the adaptive immune response and
ignore innate immunity. INmune Bio harnesses the innate immune system with a
targeted biomarker approach. . . . The company’s INKmune drug is a biologic
therapy. INKmune primes NK cells to eliminate minimal residual disease, which
is a major cause of cancer relapse and death. NK cells play a vital role in
preventing cancer. Later this year, the company expects to begin enrolling
patients in a phase I/II trial for women with relapsed refractory ovarian
cancer.”
To view the full article, visit http://ibn.fm/IvK8s
About INmune Bio Inc.
INmune Bio Inc. (NASDAQ: INMB) is a publicly traded,
clinical-stage biotechnology company developing therapies targeting the innate
immune system to fight disease. INmune Bio is developing three product
platforms: two products that re-engineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that is currently
focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell
therapeutic that primes the patient’s NK cells to attack minimal residual disease,
the remaining cancer cells that are difficult to detect, which often cause
relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often
cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors.
XPro1595 targets neuroinflammation, which causes microglial activation and
neuronal cell death. INmune Bio’s product platforms utilize a precision
medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more, please
visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment